Middle East And Africa Lipid Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 496.85 Million |
 Taille du marché (année de prévision) |
USD 878.32 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché des lipides au Moyen-Orient et en Afrique, par type (lipides naturels et lipides synthétiques), système lipidique (lipides neutres, lipides bactériens, lipides fluorescents, lipides bioactifs, lipides polymérisables, lipides modifiés par groupe de tête et autres), système de distribution (lipides, nanoparticules lipidiques solides , transporteurs lipidiques nanostructurés, niosomes, transférosomes et autres), source (jaune d'œuf, soja, soja non OGM, huiles purifiées, acides gras purifiés et autres), utilisateur final (industries pharmaceutiques, industries biotechnologiques, instituts universitaires et de recherche, industries cosmétiques et autres), canal de distribution (appel d'offres direct, ventes au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des lipides au Moyen-Orient et en Afrique
La prévalence croissante des maladies chroniques à l'échelle mondiale a accru la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent fortement sur divers lancements de produits et approbations de médicaments au cours de cette période cruciale. En outre, la demande croissante de lipides dans diverses autres industries telles que l'industrie alimentaire et des boissons, l'industrie cosmétique et d'autres, contribue également à la demande croissante du marché des lipides.
L'augmentation des dépenses de santé et les initiatives stratégiques des acteurs du marché offrent des opportunités au marché. Cependant, les différents défis de fabrication pour la production de nanoparticules lipidiques et le manque d'établissements de santé dans les économies émergentes constituent des défis majeurs pour la croissance du marché.
Le marché des lipides du Moyen-Orient et de l'Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 7,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 878,32 millions USD d'ici 2030 contre 496,85 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2015) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type (lipides naturels et lipides synthétiques), système lipidique (lipides neutres, lipides bactériens, lipides fluorescents, lipides bioactifs, lipides polymérisables, lipides modifiés par groupe de tête et autres), système de distribution (liposomes, nanoparticules lipidiques solides , transporteurs lipidiques nanostructurés, niosomes, transférosomes et autres), source (jaune d'œuf, soja, soja non OGM, huiles purifiées, acides gras purifiés et autres), utilisateur final (industries pharmaceutiques, industries biotechnologiques, instituts universitaires et de recherche, industries cosmétiques et autres), canal de distribution (appel d'offres direct, ventes au détail et autres) |
|
Pays couverts |
Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Middle East and Africa Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry |
Market Definition
Lipids can be defined as a group of organic compounds found in animals, plants, and micro- organisms. They include sterols, waxes, fats, and fat soluble vitamins. Lipids hold an ability to execute various activities. At the same time, they are known for having low toxicity levels. These qualities of lipids help in effective drug delivery. As a result, they are increasingly used as excipients in the drug production. This factor is fueling the growth of the Middle East and Africa pharmaceutical lipids market.
In recent period, the worldwide healthcare sector is going through remarkable changes. Development in drug delivery technology along with the incorporation of drug formularies is working as a driver for the growth of the pharmaceutical lipids market. Growth in quick chronic health issues and quick resulting drug delivery to the patient is one of the key factors pushing the growth of the Middle East and Africa pharmaceutical lipids market.
Lipids Market Dynamics
Drivers
-
Increase in the prevalence of chronic diseases
The encumbrance of chronic disease is briskly increasing across the globe. According to the WHO (World Health Organization), in 2021, the contribution of chronic disease was about 60%, which accounted for the number of deaths. In most Western countries, the major reason behind the increasing number of chronic diseases is the continuous increase in the aged population. The rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to an increase in the demand for various medicinal drugs that will drive the growth of the Middle East and Africa lipids market in the coming years.
-
Rising demand for lipids in food and beverage as well as the cosmetic industry
The demand for lipids in pharmaceuticals is very high as it is used in developing various drugs in the market. Also, the demand for lipids has increased in various other industries, such as in food & beverage and cosmetic products.
Lipids are an essential ingredient in the formulation of dietary supplements owing to their high content of energy and fat-soluble vitamins. Increasing health concern among people in light of COVID-19 has propelled the Middle East and Africa demand for dietary supplements. Furthermore, the availability of dietary supplements in multiple forms and flavours has made them more socially acceptable to all age groups. Growing dietary supplement consumption is expected to boost the demand for lipids over the projected years.
-
Rise in drug development
In the pharmaceutical industry, lipids and polymers are considered pillar excipients for formulating various drugs. They are used as stabilizers, solubilizes, permeation enhancers, and transfection agents. Increasing adoption of a wide range of natural, synthetic, semi-synthetic or completely artificial lipids and polymers in the formulation of various dosage forms is expected to boost the market over the forecast period.
Opportunities
-
Rise in healthcare expenditure
Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for various diseases is highly prevalent in recent years.
-
Strategic initiatives by major players
Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. Evonik invested in the short-term growth of its specialty lipids production at its Hanau and Dossenheim locations in Germany, which supplied two of the four lipids for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.
Restraints/Challenges
High cost of lipid synthesis and increasing cost of raw materials
Lipid based drugs require a huge cost for the development process. As the concept needs to be locked down, the materials need to be sourced, and it is important to consider lead times. Additionally, the process is time consuming as the drug needs sufficient time to fulfil all the clinical trials before bringing in the market for use.
Furthermore, any changes that must be re-verified will impact time. The growing advancements in biosensor assay formats and other complementary technologies demanded an effective investment for successful operations and a project risk management plan. The establishment of R&D for conducting research entails high costs, leading to expensive drugs. Thus, this factor is a major restraint for the Middle East and Africa lipids market.
- Different manufacturing challenges for lipid nanoparticle production
Lipid nanoparticles have made a major impact on the pharmaceutical industry. At their core, lipid nanoparticles (LNPs) are delivery carriers that safeguard nucleic acids. As an integral part of recent mRNA vaccines, they are injected and transported to the intended site in the cell. Despite the many advantages of lipid nanoparticles as delivery systems, the pharmaceutical industry must address significant manufacturing challenges.
These challenges include:
- Precisely controlled particle size/size distributions
- Sterilization issues
- Process repeatability and scalability
- Regulatory requirements (such as cGMP regulations)
Post COVID-19 Impact on Lipids Market
The COVID-19 has positively affected the market. As the demand for COVID-19 vaccine was on the great demand and the positive point here is the lipid is majorly used in the vaccine production. Thus COVID-19 affected lipids market positively.
Recent Developments
- In November 2022, BioNTech SE announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its Middle East and Africa footprint in Asia.
- In September 2021, U.S. ingredients supplier ABITEC Corporation signed an amended agreement with DKSH to distribute its specialty lipids into new markets and regions across Europe. This has helped the company to expand its business in various regions.
Middle East and Africa Lipids Market Scope
Middle East and Africa lipids market is segmented into, type, lipid systems, delivery systems, source, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Natural Lipid
- Synthetic Lipids
On the basis of type, the Middle East and Africa lipids market is segmented into natural lipid and synthetic lipid.
Lipid Systems
- Bioactive Lipids
- Polymerizable Lipids
- Fluorescent Lipids
- Bacterial Lipids
- Neutral Lipids
- Headgroup Modified Lipids
- Others
Based on lipid systems, the Middle East and Africa lipids market is segmented into neutral lipids, bacterial lipids, fluorescent lipids, bioactive lipids, polymerizable lipids, headgroup modified lipids and others.
Delivery Systems
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructures Lipid Carrier
- Transferosomes
- Niosomes
- Others
Based on delivery systems, the Middle East and Africa lipids market is segmented into liposomes, solid lipid nanoparticles, nanostructures lipid carrier, niosomes, transferosomes and others.
Source
- Purified Fatty Acids
- Purified Oils
- Egg Yolk
- Soyabean
- Non-GMO Soyabean
- Others
Based on source, the Middle East and Africa lipids market is segmented into egg yolk, soyabean, non-GMO soyabean, purified oils, purified fatty acids and others.
End User
- Pharmaceutical Industries
- Biotechnology Industries
- Cosmetic Industry
- Academic and Research Institutes
- Others
Based on end user, the Middle East and Africa lipids market is segmented into pharmaceutical industries, biotechnology industries, academic and research institutes, cosmetic industries and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Based on distribution channel, the Middle East and Africa lipids market is segmented into direct tender, retail sales and others.
Lipids market Regional Analysis/Insights
The lipids market is analysed and market size insights and trends are provided by country, type, lipid systems, delivery systems, source, end user and distribution channel.
Countries covered in lipids market are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, and Rest of Middle East and Africa.
South Africa is expected to grow due to a rise in chronic diseases owing to high demand for pharmaceutical drugs and rising demand for lipids in different industries are expected to drive the regional market in the forecasted period.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lipids Market Share Analysis
The lipids market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on lipids market.
Some of the major players operating in the lipids market are Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Middle East and Africa Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry among others.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LIPIDS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 MERGER AND ACQUISITION, MIDDLE EAST & AFRICA LIPIDS MARKET
4.4 PATENT ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
4.7 KEY PRICING STRATEGIES
4.8 KEY PATIENT ENROLLMENT STRATEGIES
4.9 PRICE ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET
4.1 MIDDLE EAST & AFRICA LIPIDS MARKET, CLINICAL TRIALS
4.11 MIDDLE EAST & AFRICA LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE
4.12 MIDDLE EAST & AFRICA LIPIDS MARKET, PIPELINE ANALYSIS
4.13 PHASE I CANDIDATES
4.14 PHASE I/II CANDIDATES
4.15 PHASE II CANDIDATES
4.16 PHASE III CANDIDATES
5 MIDDLE EAST & AFRICA LIPIDS MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN THE U.S.:
5.2 REGULATION IN EUROPE:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY
6.1.3 INCREASE IN DRUG DEVELOPMENT
6.2 RESTRAINTS
6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS
6.2.2 STRICT GOVERNMENT REGULATIONS
6.3 OPPORTUNITIES
6.3.1 RISE IN HEALTHCARE EXPENDITURE
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION
6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES
7 MIDDLE EAST & AFRICA LIPIDS MARKET, BY TYPE
7.1 OVERVIEW
7.2 NATURAL LIPID
7.2.1 UNSATURATED PHOSPHOLIPID
7.2.2 HYDROGENATED PHOSPHOLIPID
7.2.3 SPHINGOMYELIN
7.2.4 GLYCEROLPHOSPHOCHOLINE
7.3 SYNTHETIC LIPID
7.3.1 PEGYLATED PHOSPHOLIPIDS
7.3.2 PHOSPHATIDYLSERINE
7.3.3 PHOSPHATIDYGLYCEROLS
7.3.4 PHOSPHATIDYLETHANOLAMINE
7.3.5 PHOSPHATIDYLCHOLINE
7.3.6 PHOSPHATIDIC ACIDS
8 MIDDLE EAST & AFRICA LIPIDS MARKET, BY LIPID SYSTEMS
8.1 OVERVIEW
8.2 BIOACTIVE LIPIDS
8.2.1 PLANT LIPIDS
8.2.2 LIPID ACTIVATORS
8.2.3 LIPID INHIBITORS
8.2.4 AGONISTS
8.2.5 BIOACTIVE CERAMIDES
8.2.6 ACYL CARNITINE LIPIDS
8.2.7 ENDOCANNABINOIDS
8.2.8 LIPO-NUCLEOTIDES
8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL
8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP)
8.3 POLYMERIZABLE LIPIDS
8.3.1 FUNCTIONAL PEG LIPIDS
8.3.2 MPEG STEROLS
8.3.3 MPEG CERAMIDES
8.3.4 MPEG PHOSPHOLIPIDS
8.3.5 MPEG GLYCERIDES
8.4 FLUORESCENT LIPIDS
8.4.1 FLUORESCENT SPHINGOLIPIDS
8.4.2 FLUORESCENT GLYCEROLIPIDS
8.4.3 FLUORESCENT PEG LIPIDS
8.4.4 FLUORESCENT PHOSPHOLIPIDS
8.4.5 FLUORESCENT STEROLS
8.4.6 OTHERS
8.5 BACTERIAL LIPIDS
8.5.1 MYCOLIC LIPIDS
8.5.2 N-ACYLHOMOSERINE LIPIDS
8.5.3 BRANCHED LIPIDS
8.5.4 CYCLOPROPYL LIPIDS
8.6 NEUTRAL LIPIDS
8.6.1 PRENOLS
8.6.2 VERY LONG CHAIN FATTY ACIDS
8.6.3 GLYCERIDES
8.6.4 EICSANOIDS
8.6.5 OXYGENATED FATTY ACIDS
8.6.6 GLYCOSYLATED DIACYL GLYCEROLS
8.6.7 PROSTAGLANDINS
8.7 HEADGROUP MODIFIED LIPIDS
8.7.1 FUNCTIONAL LIPIDS
8.7.2 ANTIGENIC LIPIDS
8.7.3 GLYCOSYLATED LIPIDS
8.7.4 CHELATORS
8.7.5 ADHESIVE LIPIDS
8.7.6 SNAP-TAG REACTING LIPIDS
8.7.7 ALKYL PHOSPHATES
8.8 OTHERS
9 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS
9.1 OVERVIEW
9.2 LIPOSOMES
9.2.1 LIPOSOMES FOR DNA/RNA
9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY
9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY
9.2.2 REACTIVE LIPOSOMES
9.2.2.1 SUCCINYL LIPOSOMES
9.2.2.2 DBCO LIPOSOMES
9.2.2.3 BIOTINYLATED LIPOSOMES
9.2.2.4 CARBOXYLIC ACID LIPOSOMES
9.2.2.5 AMINE LIPOSOMES
9.2.2.6 CYANUR LIPOSOMES
9.2.2.7 AZIDE LIPOSOMES
9.2.2.8 FOLATE LIPOSOMES
9.2.2.9 DODECANYL LIPOSOMES
9.2.2.10 NI REACTIVE LIPOSOMES
9.2.2.11 PDP LIPOSOMES
9.2.2.12 GLUTARYL LIPOSOMES
9.2.2.13 OTHERS
9.2.3 DRUG LOADED LIPOSOMES
9.2.4 PLAIN LIPOSOMES
9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES
9.2.4.2 DOTAP LIPOSOMES
9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES
9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES
9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES
9.2.4.6 OTHERS
9.3 SOLID LIPID NANOPARTICLES
9.4 NANOSTRUCTURES LIPID CARRIER
9.5 TRANSFEROSOMES
9.6 NIOSOMES
9.7 OTHERS
10 MIDDLE EAST & AFRICA LIPIDS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 PURIFIED FATTY ACIDS
10.3 PURIFIED OILS
10.4 EGG YOLK
10.5 SOYABEAN
10.6 NON-GMO SOYABEAN
10.7 OTHERS
11 MIDDLE EAST & AFRICA LIPIDS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL INDUSTRIES
11.3 BIOTECHNOLOGY INDUSTRIES
11.4 COSMETIC INDUSTRIES
11.5 ACADEMIC AND RESEARCH INSTITUTES
11.6 OTHERS
12 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST & AFRICA LIPIDS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E.
13.1.4 EGYPT
13.1.5 ISRAEL
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BIONTECH SE.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 MODERNA, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PFIZER INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 CARGILL, INCORPORATED.
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KERRY.
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 ABITEC
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ADMSIO
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ALNYLAM PHARMACEUTICALS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 BASF SE
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 CAYMAN CHEMICAL
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 CD BIOPARTCLES.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CHEMI S.P.A.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 CORDENPHARMA INTERNATIONAL
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 CRODA INTERNATIONAL PLC.
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 CURIA MIDDLE EAST & AFRICA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 DSM
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 EVONIK INDUSTRIES AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 GATTEFOSSÉ
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 LIPOID GMBH
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 MATREYA, LLC
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 MERCK KGAA
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENTS
16.22 NOF EUROPE GMBH
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 STEPAN COMPANY
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD.
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 VAV LIFE SCIENCES PVT LTD
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 ASP FOR MAJOR DRUGS IN LIPIDS MARKET (PRICE IN USD)
TABLE 2 LIPID BASED NANO PARTICLE FOR COVID-19 VACCINES
TABLE 3 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 4 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 5 LIPOSOMAL FORMULATIONS
TABLE 6 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 7 LIPOSOMAL FORMULATION
TABLE 8 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 9 RNA ENCAPSULATED LIPID NANOPARTICLES
TABLE 10 LIPOSOME FORMULATIONS
TABLE 11 LIPID BASED NANO PARTICLE FOR COVID VACCINES
TABLE 12 LIPID BASED NANO PARTICLE FOR CANCER VACCINES
TABLE 13 LIPOSOMAL FORMULATION
TABLE 14 MIDDLE EAST & AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA NATURAL LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA SYNTHETIC LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA LIPOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA SOLID LIPID NANOPARTICLES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA NANOSTRUCTURES LIPID CARRIER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA TRANSFEROSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA NIOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA PURIFIED FATTY ACIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA PURIFIED OILS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA EGG YOLK IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA NON-GMO SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA PHARMACEUTICAL INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA BIOTECHNOLOGY INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA COSMETIC INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA DIRECT TENDER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA RETAIL SALES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 88 SOUTH AFRICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 89 SOUTH AFRICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 93 SOUTH AFRICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 96 SOUTH AFRICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 SOUTH AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 106 SAUDI ARABIA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 107 SAUDI ARABIA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 108 SAUDI ARABIA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 109 SAUDI ARABIA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 110 SAUDI ARABIA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 111 SAUDI ARABIA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 SAUDI ARABIA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 U.A.E. LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.A.E. NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 U.A.E. SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E. LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 120 U.A.E. NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 121 U.A.E. BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 122 U.A.E. FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 123 U.A.E. BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 124 U.A.E. POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 125 U.A.E. HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 126 U.A.E. LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 127 U.A.E. LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 128 U.A.E. LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 129 U.A.E. REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 130 U.A.E. PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 131 U.A.E. LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 132 U.A.E. LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 U.A.E. LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 EGYPT LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 136 EGYPT SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 137 EGYPT LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 138 EGYPT NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 139 EGYPT BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 140 EGYPT FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 141 EGYPT BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 142 EGYPT POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 143 EGYPT HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 144 EGYPT LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 145 EGYPT LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 146 EGYPT LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 147 EGYPT REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 148 EGYPT PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 149 EGYPT LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 150 EGYPT LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 151 EGYPT LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 152 ISRAEL LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 153 ISRAEL NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 160 ISRAEL POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 161 ISRAEL HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)
TABLE 162 ISRAEL LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 163 ISRAEL LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 164 ISRAEL LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 165 ISRAEL REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 166 ISRAEL PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)
TABLE 167 ISRAEL LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 168 ISRAEL LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 ISRAEL LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 REST OF MIDDLE EAST AND AFRICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LIPIDS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LIPIDS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LIPIDS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LIPIDS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LIPIDS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA LIPIDS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LIPIDS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LIPIDS MARKET
FIGURE 14 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022
FIGURE 19 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022
FIGURE 23 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2022
FIGURE 27 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2022
FIGURE 31 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA LIPIDS MARKET: SNAPSHOT (2022)
FIGURE 39 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022)
FIGURE 40 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY TYPE (2023 & 2030)
FIGURE 43 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
